Eliem Therapeutics Inc Stock News

WELLESLEY HILLS, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that Climb Bio has granted an inducement equity award to a new employee, pursuant to the Climb Bio's 2025 Inducement Plan, as amended, as an inducement material to the new employee ent...

PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated  Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026 Clinical trials of budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) ongoing, with initial data from both trials expected in H2 2026 Regulatory clearance obtained to initiate C...

WELLESLEY HILLS, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in the upcoming investor conferences detailed below.

WELLESLEY HILLS, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the appointments of Adam Villa as Senior Vice President, Technical Operations, and Ashley Jones as Senior Vice President, People & Workforce Strategy.

Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile, supporting development for IgA nephropathy (IgAN)

WELLESLEY HILLS, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the addition of Susan Altschuller, Ph.D.

New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL monoclonal antibody

WELLESLEY HILLS, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced details for the CLYM116 webcast event, which is set for Monday, September 29, 2025, at 8:00 a.m.